Mylan Pharmaceuticals Inc.

Consumer Healthcare Division of Pharmacia Corporation. He joined Pharmacia in 1999 as Assistant Vice President, North American Finance and Administration. At Pharmacia, Borkowski was a member of the senior management team driving the company's growth and acquisition strategy. He also established and built the Consumer Healthcare Division's global finance group, which provided streamlined business reporting to the senior leadership team. From 1992 to 1999, Borkowski served in a variety of finance positions at American Home Products, rising to the level of Comptroller for the Cyanamid Agricultural Products Division. His responsibilities at American Home Products included SEC reporting, accounting policy, banking relationships and financial modeling of M&A activities. Borkowski is a certified public accountant who began his career with Arthur Andersen. He worked primarily in its pharmaceutical practice for nearly 10 years where he served as the engagement manager for Merck & Co. Borkowski is a member of the American Institute of Certified Public Accountants and the New York State Society of CPAs. Borkowski received his bachelor's degree in economics and political science from Allegheny College and earned his MBA in finance and accounting from Rutgers University.

John Patrick O'Donnell was named Chief Scientific Officer of Mylan Laboratories Inc. in 2002. As Chief Scientific Officer, Dr. O'Donnell provides leadership and strategic direction for scientific initiatives across the Company, gathering and supervising scientific resources in order to provide an ongoing rich pipeline of new products and therapies. Prior to assuming his present position at Mylan, Dr. O'Donnell served in a variety of posts at the Company for over 20 years. Most recently Dr. O'Donnell served as Executive Vice President of Research and Quality where he was responsible for the testing and release of all finished product and intermediate testing of the finished dosage forms manufactured by Mylan production facilities. From 1987 to 1996, he served as Vice President of Research and Product Development and Vice President of Research and Quality Control. In 1994, Dr. O'Donnell developed a group devoted strictly to Clinical Research. This group's responsibility included protocol research and design as well as the execution of those clinical protocols. Clinical research was done on in-licensed compounds in both Phase II and Phase III settings to obtain FDA approval for market launch. This research included the development of clinical research studies in the therapeutic areas of cardiology, neurology and dermatology. Prior to his career with Mylan, Dr. O'Donnell taught and conducted research at West Virginia University's School of Pharmacy as a Professor of Medicinal Chemistry. He continues to serve as an Adjunct Professor of Medicinal Chemistry at WVU. Dr. O'Donnell received his Ph.D. in medicinal chemistry from the School of Pharmacy, University of Iowa in 1974. He received a master of science in medicinal chemistry from the School of Pharmacy at the State University of New York at Buffalo in 1971. Dr. O'Donnell received his bachelor of science in chemistry from Gannon College in 1969.

Wendy Cameron was appointed to the Board of Directors of Mylan in 2002. Ms. Cameron is a member of the Mylan Compensation and Governance and Nominating Committees. Ms. Cameron currently serves as chairman of the Washington Hospital Board of Trustees and Chairman of the Washington Hospital Executive Committee. She has been a member of the Board of Trustees since 1997 and a board member of the Washington Hospital Foundation since 1993. Washington Hospital, located in Washington County, Pennsylvania, is the county's largest employer. From 1981 to 1998, Ms. Cameron served as Vice President, Divisional Sales and Governmental Affairs for Cameron Coca-Cola Bottling Company, Inc., one the nation's largest bottlers. Ms. Cameron received a bachelor of science in business management and a bachelor of science in equine science from Otterbine College in Westerville, Ohio in 1981.

Greg DeMasi has worked at Mylan Pharmaceuticals since 2002 and is currently a Senior Financial Analyst in the Accounting Department. He obtained a Bachelor's Degree in Accounting and a Master's Degree in Public Accounting from WVU. He appreciates the opportunity to contribute to MTC's continued growth and success because of the value that MTC provides to the children and the community.

Milan (Mike) Puskar was elected to the Board of Directors of Mylan in 1976. He has served as Chairman of the Board of Mylan since 1993. Mr. Puskar co-founded Mylan in 1961 as a privately owned generic drug company. For the next 11 years, Mr. Puskar spearheaded the growth of the company from its early days as solely a distributor to its first manufacturing operations in 1965. By 1969, Mylan was recognized in the pharmaceutical industry as a competitive manufacturer of quality generic products. Mr. Puskar left the company in 1972 and served as Vice President and General Manager of the Cincinnati division of ICN Pharmaceuticals Inc. until 1975, when he became a partner of Elan Corporation in Dublin, Ireland. In 1976, Mr. Puskar returned to Mylan and served as President until 2000. He was elected Vice Chairman of the Board of Directors in 1980 and was elected Chairman of the Board and appointed Chief Executive Officer in 1993. He served as CEO until 2002. In addition to his management responsibilities at Mylan, Mr. Puskar served on the Commission for the Federal Drug Approval Process from 1981 to 1982; was one of the founders of the Generic Pharmaceuticals Industry Association; has been an adjunct assistant professor at the West Virginia University School of Pharmacy since 1979; and served on the board of Duquesne University in Pittsburgh, Pennsylvania. Mr. Puskar received a bachelor of science in engineering from Youngstown State University. He also received an honorable discharge from the U.S. Army, where he had achieved a top-secret clearance.

Randall "Pete" Vanderveen was elected to the Board of Directors of Mylan Laboratories in 2002. He is a member of the Mylan Compliance Committee.

Joseph C. Maroon, M.D. was appointed to the Board of Directors of Mylan in 2003. He is also a member of Mylan's Compensation Committee. Dr. Maroon has over 30 years of experience as a practicing neurosurgeon. He is regarded as a premiere specialist in the surgical treatment of injuries and diseases of the brain and spine, particularly with microscopic and minimally invasive procedures. His research into brain tumors, concussions and diseases of the spine have led to many innovative techniques for diagnosing and treating these disorders. Dr. Maroon currently serves as Professor, Heindl Scholar in Neuroscience and Vice Chairman of the Department of Neurosurgery, University of Pittsburgh Medical Center ("UPMC"), where he was previously Chief of Neurosurgery from 1972 to 1984. He is on the medical staffs of UPMC Presbyterian and Sewickley Valley Hospitals, and maintains a neurosurgical practice in Wheeling, West Virginia. Prior to rejoining UPMC, Dr. Maroon served as Professor and Chairman of the Department of Neurosurgery, Allegheny General Hospital from 1984 to 1999 and Professor and Chairman of the Department of Surgery, Allegheny General Hospital from 1995 to 1998. In 1986, Dr. Maroon was the President of the Congress of Neurological Surgeons, the largest neurological society in North America. He also served on the Board of Directors of the Think First National Head and Neck Injury Prevention Society and the American Youth Foundation, St Louis, Missouri. Additionally, Dr. Maroon has been the team neurosurgeon for the Pittsburgh Steelers since 1981. He is a co-founder of the UPMC Sports Medicine Concussion Program and a co-developer of the world's first computerized sports concussion evaluation system, ImPACT© (Immediate Post-Concussion Assessment and Cognitive Testing), a tool used by team doctors and athletic trainers nationwide to help determine the severity of a concussion and when it is safe for an athlete to return to play following injury. Dr. Maroon has earned numerous awards for his contributions to neurosurgery from various national and international neurological societies throughout his career. He is the author or co-author of 40 book chapters in addition to more than 250 published scientific papers. He has edited three additional books, has given more than 140 national and international presentations, often as a visiting professor, and has served on the editorial boards of five neurological journals. Consistently listed in "America's Best Doctors," Dr. Maroon's patients travel from all over the world to seek his care. Dr. Maroon received his undergraduate and medical education at the University of Indiana. Following his graduation from medical school in 1965, he served residencies in neurosurgery at Indiana University, Georgetown University and the Radcliffe Infirmary at Oxford University in England. He received a Fellowship from the University of Vermont where he studied microsurgery, as the Given Scholar in Microneurosurgery.

Robert J. Coury has served as Mylan's Vice Chairman and Chief Executive Officer since 2002. During his tenure, the company has been transformed from the third largest generics company in the United States to the third largest generics and specialty pharmaceutical company in the world with the acquisitions of a majority interest in Matrix Laboratories -- of which Coury is now Chairman -- and the global generics business of Merck KGaA. Prior to joining Mylan, Coury was the principal of Coury Consulting L.P., a corporate strategy advisory firm he formed in 1989 in Pittsburgh, Pennsylvania.